1Department of Clinical Pharmacy, College of Pharmacy, Taif University, Taif, KSA
2Department of Pharmacology, Faculty of Medicine, Tanta University, Tanta, Egypt
33Pharm D Student, College of Pharmacy, Taif University, Taif, KSA
Journal of Cancer Research and Treatment.
2017,
Vol. 5 No. 3, 100-104
DOI: 10.12691/jcrt-5-3-5
Copyright © 2017 Science and Education PublishingCite this paper: Ahmed M. Kabel, Nourah Alqahtani, Rawan Alshehri, Aminah Altalhi, Bashair Alqurashi. Multiple Myeloma: New Perspectives.
Journal of Cancer Research and Treatment. 2017; 5(3):100-104. doi: 10.12691/jcrt-5-3-5.
Correspondence to: Ahmed M. Kabel, Department of Clinical Pharmacy, College of Pharmacy, Taif University, Taif, KSA. Email:
drakabel@gmail.comAbstract
Multiple myeloma (MM) is the most common bone malignancy that occurs frequently in older persons. It is the second most common blood cancer in which the patient usually presents with bone pain, nausea, malaise, anemia, renal insufficiency and hypocalcaemia. There is a wide variety of risk factors that may predispose to MM. It is usually discovered on routine laboratory investigations and usually diagnosed with serum or urine protein electrophoresis or immunofixation and bone marrow aspirate analysis. MM often has bad prognosis, although advances in therapy resulted in significant improvement in the overall survival rate. This review sheds light on the incidence, etiology, clinical presentation, the methods of diagnosis, prognosis and the possible lines of management of MM.
Keywords